Total Payments
$43,644
2024 Payments
$451.68
Companies
20
Transactions
220
Medicare Patients
921
Medicare Billing
$46,783
Payment Breakdown by Category
Other$34,485 (79.0%)
Travel$5,378 (12.3%)
Food & Beverage$3,778 (8.7%)
Education$2.38 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,485 | 24 | 79.0% |
| Travel and Lodging | $5,378 | 24 | 12.3% |
| Food and Beverage | $3,778 | 171 | 8.7% |
| Education | $2.38 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $25,865 | 84 | $0 (2024) |
| ITI, Inc. | $15,714 | 30 | $0 (2023) |
| Alkermes, Inc. | $476.23 | 21 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $293.43 | 14 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $280.12 | 16 | $0 (2024) |
| ABBVIE INC. | $184.11 | 11 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $151.79 | 7 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $138.91 | 7 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $100.68 | 6 | $0 (2023) |
| Corium, LLC | $71.93 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $451.68 | 23 | ABBVIE INC. ($72.29) |
| 2023 | $482.48 | 25 | Teva Pharmaceuticals USA, Inc. ($95.61) |
| 2022 | $325.19 | 19 | Vanda Pharmaceuticals Inc. ($59.84) |
| 2021 | $9,021 | 25 | ITI, Inc. ($8,884) |
| 2020 | $6,893 | 19 | ITI, Inc. ($6,776) |
| 2019 | $10,140 | 43 | Otsuka America Pharmaceutical, Inc. ($9,677) |
| 2018 | $8,084 | 30 | Otsuka America Pharmaceutical, Inc. ($7,973) |
| 2017 | $8,246 | 36 | Otsuka America Pharmaceutical, Inc. ($8,023) |
All Payment Transactions
220 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $21.86 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/30/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: Neurology | ||||||
| 10/08/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: PSYCHIATRY | ||||||
| 10/01/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.08 | General |
| Category: PSYCHIATRY | ||||||
| 09/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: PSYCHIATRY | ||||||
| 06/25/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 06/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: NEUROSCIENCE | ||||||
| 06/11/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: Neuropsychiatry | ||||||
| 06/05/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 05/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: NEUROSCIENCE | ||||||
| 05/07/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: CNS | ||||||
| 04/16/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: CNS | ||||||
| 04/02/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Insomnia | ||||||
| 03/24/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Neuroscience | ||||||
| 03/19/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: PSYCHIATRY | ||||||
| 03/11/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: CNS | ||||||
| 03/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: NEUROSCIENCE | ||||||
| 02/28/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Neuroscience | ||||||
| 02/14/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: CNS | ||||||
| 02/07/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 01/23/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/06/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2023 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Central Nervous System | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 152 | 394 | $21,533 | $9,437 |
| 2022 | 3 | 204 | 497 | $22,450 | $10,893 |
| 2021 | 3 | 263 | 430 | $20,169 | $11,118 |
| 2020 | 1 | 302 | 540 | $23,625 | $15,335 |
Total Patients
921
Total Services
1,861
Medicare Billing
$46,783
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 122 | 357 | $18,414 | $7,652 | 41.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 21 | $2,305 | $1,416 | 61.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 16 | $813.75 | $369.32 | 45.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 146 | 394 | $17,238 | $8,328 | 48.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 16 | 20 | $1,750 | $1,312 | 75.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 29 | 38 | $1,663 | $898.98 | 54.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Facility | 2022 | 13 | 45 | $1,800 | $353.65 | 19.6% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 124 | 268 | $11,725 | $6,696 | 57.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 25 | 31 | $2,713 | $2,025 | 74.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 49 | 66 | $2,888 | $1,463 | 50.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 49 | 49 | $2,144 | $616.75 | 28.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 16 | 16 | $700.00 | $317.20 | 45.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 162 | 272 | $11,900 | $8,220 | 69.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 140 | 268 | $11,725 | $7,115 | 60.7% |
About Dr. Patrick Stang, MD
Dr. Patrick Stang, MD is a Psychiatry healthcare provider based in Great Bend, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639100183.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Stang, MD has received a total of $43,644 in payments from pharmaceutical and medical device companies, with $451.68 received in 2024. These payments were reported across 220 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($34,485).
As a Medicare-enrolled provider, Stang has provided services to 921 Medicare beneficiaries, totaling 1,861 services with total Medicare billing of $46,783. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Great Bend, KS
- Active Since 07/05/2006
- Last Updated 03/18/2025
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1639100183
Products in Payments
- REXULTI (Drug) $25,474
- CAPLYTA (Drug) $15,763
- ABILIFY MAINTENA (Drug) $354.34
- ARISTADA (Drug) $297.97
- INGREZZA (Drug) $280.12
- VRAYLAR (Drug) $184.11
- Aristada 441 mg (Drug) $178.26
- SPRAVATO (Drug) $164.91
- INVEGA SUSTENNA (Drug) $128.52
- HETLIOZ (Drug) $115.32
- TRINTELLIX (Drug) $114.46
- ABILIFY ASIMTUFII (Drug) $83.02
- UZEDY (Drug) $79.11
- Azstarys (Drug) $71.93
- QELBREE (Drug) $53.50
- LATUDA (Drug) $53.26
- AUSTEDO (Drug) $53.19
- Auvelity (Drug) $39.29
- Adzenys XR-ODT (Drug) $33.44
- Trintellix (Drug) $31.49
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.